Over the past 40 years, cooperative research efforts (primarily through the Children’s Oncology Group) have resulted in dramatic increases in cure rates for most pediatric cancers.
Nevertheless, substantial numbers of children with cancer still succumb to their disease, and even larger numbers of pediatric patients suffer significant long-term late effects because of the intensity of the therapies required to achieve cure. Research into the pathophysiologic mechanisms underlying pediatric tumors is essential to develop novel therapeutic approaches that will yield higher rates of cure and fewer side effects.
Duke investigators have a strong history of involvement in both clinical and basic research arenas and have contributed to cutting-edge advances in both understanding and treating a variety of pediatric tumors. The Pediatric Cancer disease group encompasses logical intersections with DCI disease-based programs in Brain Tumor (incorporating neuroblastoma), Hematologic Malignancies, and Sarcoma. The program includes:
Through these collaborative efforts, the program will contribute to further improving our understanding of how pediatric cancers arise, and developing new treatment paradigms that will lead to higher cure rates and less morbidity.
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More